Couverture de Construction stocks, XPS & medtech: The Companies and Markets Show

Construction stocks, XPS & medtech: The Companies and Markets Show

Construction stocks, XPS & medtech: The Companies and Markets Show

Écouter gratuitement

Voir les détails

À propos de cette écoute

The show starts unpacking the latest results from equipment hire company Ashtead (AHT). Mark Robinson analyses the outlook for US construction spending, the company’s sensitivity to tariffs and its valuation. It’s then on to Ashtead’s smaller rival Speedy Hire (SDY), which is closing some of its depots due to rising staff costs. Listen to find out everything investors need to know.


Next up is one of the IC's Ideas of the Year, which are putting in a strong performance again in 2025. Pensions consultancy XPS Pensions (XPS) reported full-year figures earlier this week – Julian Hofmann asks if its booming business can continue.


Lastly, our Big Read on the medical technology sector. Mark Robinson covers the issues facing the industry, the options for investors and a potential tariff winner.


Timestamps

1:50 Ashtead

9:20 Speedy Hire

18:29 XPS Pensions

27:36 Medtech


Read more on these topics:

Ashtead stymied by falling used equipment sales

Speedy Hire attempts to boost efficiencies as HMRC loads costs

The cutting-edge medtech stocks worth owning


Listen to more podcasts from Investors’ Chronicle on Apple, Spotify and YouTube

Hosted on Acast. See acast.com/privacy for more information.

Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !

    Ce que les auditeurs disent de Construction stocks, XPS & medtech: The Companies and Markets Show

    Moyenne des évaluations utilisateurs. Seuls les utilisateurs ayant écouté le titre peuvent laisser une évaluation.

    Commentaires - Veuillez sélectionner les onglets ci-dessous pour changer la provenance des commentaires.

    Il n'y a pas encore de critique disponible pour ce titre.